| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
PTC Therapeutics (NASDAQ:PTCT) reported its Q4 earnings results on Thursday, February 29, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
PTC Therapeutics missed estimated earnings by -148.0%, reporting an EPS of $-0.24 versus an estimate of $0.5.
Revenue was up $139.64 million from the same period last year.
Last quarter the company missed on EPS by $0.59 which was followed by a 23.0% drop in the share price the next day.
Here's a look at PTC Therapeutics's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -1.17 | -1.58 | -1.39 | -1.59 |
| EPS Actual | -1.76 | -1.48 | -1.88 | -1.89 |
| Revenue Estimate | 210.19M | 213.95M | 182.62M | 189.14M |
| Revenue Actual | 196.58M | 213.81M | 220.38M | 167.41M |
To track all earnings releases for PTC Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: PTCT
